A date for your diary: the next course an “Update on Pharmacoeconomics in the Irish Healthcare Setting” will take place on 30th and 31st March 2017. This course is now full – no more places available. Course Programme 2017
Following NCPE assessment of Trametinib (Mekinist®) it is not considered cost-effective and therefore not recommended for reimbursement at the submitted price.
Following NCPE assessment of daratumumab (Darzalex®) monotherapy, it is not considered cost-effective and therefore is not recommended for reimbursement.